Advanced Biomed Shares Soar 39% on Breakthrough Microfluidic Oncology Chips
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Advanced Biomed Inc (NASDAQ: ADVB) is a biotechnology company focused on the research, development, and manufacture of microfluidic biochip technologies for precision oncology diagnosis and treatment. As of October 21, 2025, ADVB shares closed at $0.6017, a 39.31 percent gain on a trading volume of 5,116,241 shares on the Nasdaq Capital Market.
| Exchange | Ticker | Price | Change (%) | Volume |
|---|---|---|---|---|
| Nasdaq Capital Market (NAS) | ADVB | $0.6017 | +39.31% | 5,116,241 |
Corporate Structure
Founded in 2014 and headquartered in Tainan, Taiwan, Advanced Biomed has developed an integrated microfluidic technology platform that encompasses research and development, chip design, and manufacturing. The company’s product portfolio includes:
- A+Pre, an automated sample-preparation system designed to reduce blood viscosity
- AC-1000, a rare-cell enrichment device
- A+SCDrop, a single-cell capture unit
- A+CellScan, an analyzer for immunostained cells
Advanced Biomed also offers four immunostaining kits: A+CTCE, A+CTCM, A+EMT, and A+CM. Additionally, it has launched A+LCGuard, a lung-cancer screening assay to assist in distinguishing between benign and malignant pulmonary nodules. The company’s primary operations and development are based in Taiwan, with ongoing expansion efforts in China and plans to establish centers in North America and Europe.
Microfluidic technology by CDC
Recent Developments and News
- March 6, 2025: Advanced Biomed priced its initial public offering at $4.00 per share, raising gross proceeds of $6.56 million from the issuance of 1,640,000 shares, with a 45-day over-allotment option for up to 246,000 additional shares.
- March 7, 2025: The IPO formally closed. Proceeds from the offering are allocated for in vitro diagnostics clinical research, chip design and development, facility upgrades, market expansion, and general working capital.
- Mid-2025: Results from pre-mass production trials indicated that the A+Pre chip achieved a 94 percent recovery rate of circulating tumor cells, while the AC-1000 recorded a 79.5 percent recovery rate, achieving established performance targets.
- 2025: Both the A+Pre and AC-1000 devices received clearance from China’s National Medical Products Administration. Advanced Biomed has established manufacturing partnerships with Riva and Unimold to increase chip production capacity.
Financial and Strategic Analysis
Since its IPO in March 2025, Advanced Biomed has utilized the $6.56 million in gross proceeds to advance its in vitro diagnostics pipeline. The allocation is aimed at supporting chip development, clinical validation, and market outreach initiatives. The current share price of $0.6017 is below the $4.00 offering price; however, the 39.31 percent increase on October 21 indicates renewed interest in the stock.
Strategically, the company employs a semiconductor-based, antigen-independent methodology to capture circulating tumor cells and related biomarkers, which distinguishes its approach from conventional antibody-based liquid biopsies. This microfluidic platform enables Advanced Biomed to potentially offer comprehensive solutions for early screening, diagnosis, staging, and single-cell analysis—important areas within the oncology diagnostics market.
Market Position and Industry Context
The global early-detection market is growing as healthcare providers seek rapid and cost-effective alternatives to traditional biopsies. Advanced Biomed competes with companies that utilize circulating tumor DNA (ctDNA) assays—such as Grail’s multi-cancer tests and Labcorp’s plasma-based panels—by focusing on intact cell recovery and analysis. Its antigen-independent approach may capture a broader range of tumor cells, allowing it to address some limitations associated with variable surface markers.
With regulatory approvals in China and established manufacturing partnerships, Advanced Biomed is positioned to gain market share in Asia and plans to expand its platform into North America and Europe. The anticipated clinical evaluation of the A+LCGuard lung screening kit will further enhance its product offerings in a critical segment of cancer diagnostics.
tl;dr
On October 21, 2025, ADVB closed at $0.6017 (+39.31%) on 5.1 million shares. Since its March 2025 IPO, Advanced Biomed raised $6.56 million to support in vitro diagnostics research, chip development, and market expansion. The company’s core devices have secured NMPA clearance and achieved over 90% cell-recovery rates in pre-production trials. Manufacturing partnerships are established, and clinical evaluation of its lung-cancer screening kit is underway. Operations are set to expand from Taiwan and China into North America and Europe.